ASPIRIN – YURAK SOG‘LIGINING HIMOYACHISI.
Abstract
Bugungi kunda yurak-qon tomir kasalliklari butun dunyo bo‘ylab eng ko‘p uchraydigan va eng xavfli kasalliklar sirasiga kiradi. Infarkt, insult kabi holatlar ko‘pincha to‘satdan sodir bo‘ladi va inson hayotiga jiddiy xavf tug‘diradi. Ammo ularni oldini olish, xavfini kamaytirish mumkin. Bunda esa eng oddiy, lekin juda muhim vositalardan biri – bu aspirin hisoblanadi.
References
World Health Organization (WHO). Cardiovascular diseases (CVDs) fact sheet. WHO, 2023.
Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. The Lancet, 2009; 373(9678): 1849–1860.
Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med, 2005; 353: 2373–2383.
European Society of Cardiology (ESC). Guidelines for cardiovascular disease prevention in clinical practice. Eur Heart J, 2021.
Yusuf S, Joseph P, Dans A, et al. Primary and secondary prevention of cardiovascular disease with aspirin and other antiplatelet drugs: a worldwide perspective. Circulation, 2016; 134(10): 695–710.
O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. Kardiologiya bo‘yicha klinik protokollar. Toshkent, 2022.
Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang and Dale’s Pharmacology. 9th ed. Elsevier, 2020.
Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. McGraw-Hill, 2018.
